Press – July 7, 2017

Witty Health Inc. appoints Karthik Koduru, MD as Chief Oncologist as Company Extends its monitoring platform to Oncology Market

Houston, TX – July 5, 2017 – Witty Health Inc., a real-time remote health risk monitoring company, today announced the appointment of Dr. Karthik Koduru, MD as Chief Oncologist of the company. In his role as the Chief Oncologist, Dr. Koduru will oversee the company’s product strategy for oncology market and pilot the validation of Witty Health’s Cancer Treatment Platform (CTP™) at major cancer centers.

“We are excited to have Dr. Karthik Koduru join our core leadership team,” said Co-Founder Ram Sesha. “We are in advanced discussions with multiple biopharmaceutical companies and cancers centers for partnership. Dr. Koduru’s expertise in cancer care with innovative medicines will enable Witty Health to actively expand its platform to oncology market and enable pharmaceutical and biotech company collaborations to improve outcomes of cancer drugs.”

“The current cancer treatment model without monitoring patient’s condition between office visits is not working. Witty Health’s Cancer Treatment Platform (CTP™) is designed for value-based models where the patient’s symptoms and vitals are monitored in real-time to improve patient’s Quality of Life (QoL) and potentially disease outcomes. Through an engaging partnership with payers, cancer drug marketers and physicians, we believe our product can significantly reduce preventable healthcare costs by reducing ER visits and hospitalizations due to symptom exacerbations,” stated Dr. Koduru.

Witty Health’s Cancer Treatment Platform (CTP™) is connected with eight devices: a wireless weighing scale, blood pressure cuff, pulse oximeter, stethoscope, thermometer, multi-scope camera, ECG and blood glucose monitor. These tools create data which can be remotely uploaded while the patient is video conferencing with the physician – in real-time or offline, from home or office. Cancer Treatment Platform (CTP™) includes drug specific toxicity pathways to help oncologists to address specific toxicity effectively and promptly to improve Quality of Life (QoL) and potentially improve outcomes of the treatment.

It is protected by a number of novel patent applications covering the treatment with Checkpoint, CDK 4/6 and PARP inhibitors and pain management during cancer therapy. The Cancer Treatment Platform (CTP™) is customizable to five Checkpoint inhibitors; Opdivo, Keytruda®, Imfinzi, TecentriQ® and Bavencio, three CDK 4/6 inhibitors: Ibrance®, Abemaciclib, and Kisqali®, PARP inhibitor; Lynparza and for any pain medication.

Witty Health Inc was established with the aim of finding new models to combat chronic care diseases through an intelligent, remote health risk monitoring technology. The company uses the InstaMD platform which includes: a telemedicine-based remote clinic, home health monitoring, patient diagnosis, and messaging application modules. The suite of intelligent tools for this platform helps personalize health risk management. Witty Health Inc. has assembled an experienced management team and promoted by a number of outstanding physician/oncology leaders.

For further information about Witty Health and its Cancer Treatment Platform (CTP™), please visit

About Witty Health

Witty Health, Inc. ( is a Houston, TX-based technology company focusing on intelligence-powered, real-time health risk monitoring for clinical prevention. Witty Health, privately held by employees and outstanding physician/oncology leaders, is redefining the immunotherapy-based cancer treatments through the development and commercialization of its proprietary Cancer Treatment Platform (CTP™). ­­­­­­­

Media Contact:
Contact Person: Ram Sesha
Witty Health Inc.
5850, San Felipe, Suite 500
Houston. TX 77057

Phone: (713) 470-2580

This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.

Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest investor report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.